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Abstract
Background: Low dose naltrexone (LDN) is reported to have beneficial effects in several autoimmune diseases. The
purpose of this study was to examine whether starting LDN was followed by changes in the dispensing of thyroid
hormones to patients with hypothyroidism.
Methods: We performed a quasi-experimental before-after study based on the Norwegian Prescription Database.
Study participants were identified by using reimbursement codes for hypothyroidism. Cumulative dispensed
Defined Daily Doses and the number of users of triiodothyronine (T3) and levothyroxine (LT4) 1 year before and
after the first LDN prescription was compared in three groups based on LDN exposure.
Results: We identified 898 patients that met the inclusion criteria. There was no association between starting LDN
and the subsequent dispensing of thyroid hormones. If anything, there was a tendency towards increasing LT4
consumption with increasing LDN exposure.
Conclusion: The results of this study do not support claims of efficacy of LDN in hypothyroidism.
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Background
The opioid antagonist naltrexone in low doses (typically <
5mg/day) is being used off-label against several auto-
immune diseases. In a recent review, the authors claim
that low dose naltrexone (LDN) has beneficial immuno-
modulatory effects by acting on the opioid growth factor
receptor (OGFr) or as a direct immunomodulating agent,
by elevating endogenous opioids, or by affecting cytokine
production [1].
A few small randomized clinical trials show promising
results in inflammatory bowel disease, multiple sclerosis
and chronic pain conditions [1]. Although no studies in
thyroid disease have been published, LDN has been pro-
posed as an alternative add-on to regular hypothyroid
therapy. Some patients report astounding improvements
[2], and there are patients and doctors who claim that
LDN may be beneficial in autoimmune thyroid disease,
but definitive evidence is lacking [3].
Decades of high dose naltrexone in the treatment of opi-
oid and alcohol addiction indicate that LDN has an excel-
lent safety profile [4], and with increasing awareness
among patients, it is highly likely that endocrinologists in-
creasingly will have requests to prescribe LDN.
In 2013, the number of users of LDN in Norway in-
creased from almost zero to 0.3% of the population within
few months following a TV documentary [5]. This surge
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in LDN use could be considered a natural experiment that
make quasi-experimental pharmacoepidemiological studies
possible. We seized the opportunity to examine whether
there were changes in the dispensing of thyroid hormones
in selected patients following the initiation of LDN therapy.
If LDN is actually efficacious in hypothyroidism, it is plaus-
ible that it would result in changes in the use of triiodothyr-
onine (T3) and/or levothyroxine (LT4).
Methods
This was a controlled before-after study based on data
from the Norwegian Prescription Database (NorPD). The
NorPD contains information on prescriptions dispensed
to all Norwegian residents [6]. For a fee, NorPD used re-
imbursement codes for hypothyroidism (International
Classification of Disease (ICD-10) code E03 and Inter-
national Classification of Primary Care (ICPC-2) code
T86) to identify patients in the database according to our
specifications. We received an encrypted data file allowing
us to follow individual patients without knowing their
identity. The database does not contain any other clinical
information related to thyroid disease than the prescribing
of thyroid hormones. To increase specificity, we only in-
cluded patients that collected at least two prescriptions
containing reimbursement codes for hypothyroidism in
2009 and 2010, and had collected ≥1 LDN prescriptions in
2013. We defined the first prescription in 2013 as index
data, and stratified patients in three groups according to
LDN exposure in the 2 years after index date: LDN × 1
(controls, collected LDN once), LDN × 2–3 (collected
LDN twice or thrice) and LDN × 4+ (persistent users, col-
lected LDN > 3 times). We have previously used the same
stratification in other studies [7–9].
Outcomes were differences between the cumulative
collected amounts of Defined Daily Doses (DDDs) and
the number of users of levothyroxine (LT4) and triiodo-
thyronine (T3). One DDD LT4 equals 150 μg, and one
DDD triiodothyroxine is 60 μg. We calculated the differ-
ence for each patient by subtracting the number of col-
lected DDDs of T3 and LT4 year following the first
LDN prescription from the number of DDDs in the year
preceding the first LDN prescription. All index dates
were in 2013, and the total observation time was 2 years
for all participants. The first observation date was theor-
etically January 1, 2012, and the last observation date
was December 31, 2014.
Statistical methods
The study size depended on the number of patients in
NorPD meeting our inclusion criteria. We used SPSS 25
and Excel 2013 for data management and statistical ana-
lysis, and analyzed all data on individual level. We used
a pairwise two-sided t-test to investigate the mean
changes in the sum of the DDDs per patient in each
group for all examined medicines. In addition, we calcu-
lated 95% confidence intervals (CI) for the difference of
means. Change in the number of users was expressed as
the proportion of each group, together with the 95% CI
for the difference of the proportion (in % points) [10].
Difference-in-difference of DDDs and the proportion of
users (in % points) with 95% CI were calculated.
In addition, we conducted an ANCOVA to compare
differences in T3 and LT4 dispensing before and after
index date while adjusting for sex, age in 2013, and the
number of prescriptions (all prescription medicines) col-
lected 1 year before index date.
Results
We identified 898 patients who met the inclusion cri-
teria. Baseline data are given in Table 1. There were neg-
ligible differences between groups in age, proportion
females and the cumulative number of prescriptions of
all medicines per person 1 year before index date.
Differences in DDD are shown in Table 2. There were no
T3 or LT4 DDD differences between groups before or after
starting LDN, or within groups before-after. The difference-
in-difference between LDN × 1 and LDN × 4+ for LT4 was
not significant (6.2 DDD, 95% CI − 11.3 to 23.7, p= 0.313),
but the dispensed cumulative DDD in LDN × 4+ LT4 dis-
pensing after was almost significantly larger after starting
LDN (19.8 DDD, 95% CI − 0.1 to 23.7, p = 0.060).
There were no differences in the number of users of
neither T3 nor LT4, except for a 2.0% points borderline
significant reduction in the number of LT4 users in the
LDN × 2–3 group (Table 3). There was no difference-in-
difference in number of users of LT4 between LDN × 1
and LDN × 4+ (1.2% points, 95% CI − 1,8 to 4,1, p =
0.441) or between LDN × 2–3 and LDN × 4+ (2.0%
points, 95% CI − 0.5 to 4.5, p = 0.113). For the number
of T3 users, there was no difference-in-difference be-
tween groups, for example LDN × 1 vs. LDN × 4+: 2.4%
points, 95% CI − 0.9 to 5.8, p = 0.151).
The results of the ANCOVA analyses are given in
Additional file 1. Levene’s test and normality checks
were carried out and the assumptions met. When adjust-
ing for sex, age and number of prescriptions dispensed
before index date in the model, no differences between
LDN groups in the change of dispensing was observed
Table 1 Baseline data
LDN × 1 LDN × 2–
3
LDN × 4+
N (%) 260 (29.0) 198 (22.0) 440 (49.0)
Female (%) 240 (92.3) 178 (89.9) 415 (94.3)




32.1 (38.3) 30.8 (32.6) 30.8 (13.4)
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for neither T3 (F (2, 892) = 0.53, p = 0.588)) nor LT4 (F
(2, 892) = 0.246, p = 0.782)).
Discussion
We found no association between starting LDN and
changes in the dispensing of thyroid hormones. If any-
thing, there was a tendency towards increasing LT4 con-
sumption with increasing LDN exposure.
There was a reduction in users LT4 in the group
with intermediate LDN exposure (LDN × 2–3), but
this does not suggest efficacy of LDN in
hypothyroidism. There was no significant difference-
in-difference between groups. Since the persistent
LDN users (LDN × 4+) had the least reduction in the
number of LT4 users, this finding does not fit into a
dose-response relationship.
NorPD is a reliable data source that contains almost
complete information on all prescribing outside
institutions in Norway, and the inclusion criteria
probably lead to a representative sample of the LDN
using hypothyroidism population. The strict inclusion
criteria reduced the risk of accidental misdiagnosis
and bias due to patients starting thyroid hormones
during the observation period. Register-based studies
have important limitations, and among the most im-
portant is scarce clinical information. The prescribing
of T3and LT4 are only proxies to thyroid function,
and we cannot rule out possible beneficial or negative
effects of LDN not leading to changes in the dosing
of thyroid hormones. In addition, the data did not
allow any stratification between different types of
hypothyroidism, and it was not possible to adjust for
body weight. It is possible that the use of large
amounts of thyroid hormones in obese patients could
cancel data from leaner patients. We do not believe
this was a major source of bias, since the outcome
was pairwise differences in prescribing of T3 and LT4,
not total cumulative use.
Quasi-experimental studies have limitations due to
non-random assignment, and in this study, we did
not include a control group that was unexposed to
LDN. Bias in the inclusion of patients, temporal fac-
tors such as natural course of disease and regression
to the mean are other problems associated with
before-after studies [11].
The negative findings in this study fit into the mixed
results of clinical and pharmacoepidemiological studies
on LDN in autoimmune disease [1, 8, 9].
Conclusions
The initiation of LDN therapy was not followed by
changes in the use of thyroid hormones. The results of
this study do not support claims of efficacy of LDN in
hypothyroidism.
Table 2 Average cumulative number of DDDs of thyroid hormones dispensed to patients 1 year before and after the first dispense
of LDN. Patients stratified based on the number of LDN dispenses: LDN × 1 (N = 260), LDN × 2–3 (N = 198) and LDN × 4+ (N = 440).
LDN: Low dose naltrexone. DDD: Defined daily dose
Dispensed drugs (DDD) Difference (DDD)
Before After Mean 95% CI difference p
Levothyroxine (LT4)
LDN × 1 225.4 223.1 −2.3 (−15.9 to 11.2) 0.737
LDN × 2–3 245.9 248.9 3.0 (−15.6 to 21.5) 0.754
LDN × 4+ 239.0 242.9 3.9 (−7.1 to 14.9) 0.490
Triiodothyronine (T3)
LDN × 1 10.4 10.5 0.1 (−2.8 to 3.1) 0.932
LDN × 2–3 8.1 5.9 −2.2 (−5.1 to 0.7) 0.139
LDN × 4+ 11.4 11.1 −0.3 (−2.9 to 2.3) 0.818
Table 3 The number of users of thyroid hormones dispensed 1
year before and after the first dispense of LDN. The groups are
stratified based on the number of LDN dispenses: LDN × 1 (N =
260), LDN × 2–3 (N = 198) and LDN × 4+ (N = 440). LDN: Low
dose naltrexone
Number of users Difference
Before After
N % N % % points 95%CI p
Levothyroxine (LT4)
LDN × 1 243 (93.5) 240 (92.3) −1.2 (−3.7 to 1.3) 0.366
LDN × 2–3 191 (96.5) 187 (94.4) −2.0 (−4.0 to −0.1) 0.045
LDN × 4+ 420 (95.5) 420 (95.5) 0.0 (−1.5 to 1.5) 1.000
Triiodothyronine (T3)
LDN × 1 28 (10.8) 24 (9.2) −1.5 (−4.1 to 1.1) 0.248
LDN × 2–3 15 (7.6) 11 (5.6) −2.0 (−5.1 to 1.1) 0.206
LDN × 4+ 51 (11.6) 55 (12.5) 0.9 (−1.2 to 3.0) 0.394
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